![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » British Regulatory Watchdog Lambasts Seven Pharmaceutical Companies for Code of Practice Breaches
British Regulatory Watchdog Lambasts Seven Pharmaceutical Companies for Code of Practice Breaches
April 25, 2022
The UK’s self-regulatory industry watchdog, the Association of the British Pharmaceutical Industry (ABPI) has cited seven drugmakers for violations of its code of practice — LEO Pharma, Janssen, Teva Pharmaceuticals, Lundbeck, Otsuka Europe, Daiichi-Sankyo and Roche.
LEO Pharma, for example, was dinged for promoting its psoriasis drug Enstilar (betamethasone dipropionate/calcipotriol monohydrate) before it was given marketing authorization and for its failure to disclose payments made to patient organizations in 2019.
The ABPI also issued a reprimand to Janssen for failing to “maintain oversight and high standards” in a nurse-led homecare service involving its immunosuppressive drug Stelara (ustekinumab).
Read the ABPI notice here: bit.ly/3vF7EVu.
Upcoming Events
-
21Oct